Cargando…

Novel protein biomarkers for pneumonia and acute exacerbations in COPD: a pilot study

INTRODUCTION: Community-acquired pneumonia (CAP) and acute exacerbations of chronic obstructive pulmonary disease (AECOPD) result in high morbidity, mortality, and socio-economic burden. The usage of easily accessible biomarkers informing on disease entity, severity, prognosis, and pathophysiologica...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Anna Lena, Han, Maria, Griss, Kathrin, Bertrams, Wilhelm, Nell, Christoph, Greulich, Timm, Klemmer, Andreas, Pott, Hendrik, Heider, Dominik, Vogelmeier, Claus F., Hippenstiel, Stefan, Suttorp, Norbert, Schmeck, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277477/
https://www.ncbi.nlm.nih.gov/pubmed/37342494
http://dx.doi.org/10.3389/fmed.2023.1180746
_version_ 1785060289801093120
author Jung, Anna Lena
Han, Maria
Griss, Kathrin
Bertrams, Wilhelm
Nell, Christoph
Greulich, Timm
Klemmer, Andreas
Pott, Hendrik
Heider, Dominik
Vogelmeier, Claus F.
Hippenstiel, Stefan
Suttorp, Norbert
Schmeck, Bernd
author_facet Jung, Anna Lena
Han, Maria
Griss, Kathrin
Bertrams, Wilhelm
Nell, Christoph
Greulich, Timm
Klemmer, Andreas
Pott, Hendrik
Heider, Dominik
Vogelmeier, Claus F.
Hippenstiel, Stefan
Suttorp, Norbert
Schmeck, Bernd
author_sort Jung, Anna Lena
collection PubMed
description INTRODUCTION: Community-acquired pneumonia (CAP) and acute exacerbations of chronic obstructive pulmonary disease (AECOPD) result in high morbidity, mortality, and socio-economic burden. The usage of easily accessible biomarkers informing on disease entity, severity, prognosis, and pathophysiological endotypes is limited in clinical practice. Here, we have analyzed selected plasma markers for their value in differential diagnosis and severity grading in a clinical cohort. METHODS: A pilot cohort of hospitalized patients suffering from CAP (n = 27), AECOPD (n = 10), and healthy subjects (n = 22) were characterized clinically. Clinical scores (PSI, CURB, CRB65, GOLD I-IV, and GOLD ABCD) were obtained, and interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-2-receptor (IL-2R), lipopolysaccharide-binding protein (LBP), resistin, thrombospondin-1 (TSP-1), lactotransferrin (LTF), neutrophil gelatinase-associated lipocalin (NGAL), neutrophil-elastase-2 (ELA2), hepatocyte growth factor (HGF), soluble Fas (sFas), as well as TNF-related apoptosis-inducing ligand (TRAIL) were measured in plasma. RESULTS: In CAP patients and healthy volunteers, we found significantly different levels of ELA2, HGF, IL-2R, IL-6, IL-8, LBP, resistin, LTF, and TRAIL. The panel of LBP, sFas, and TRAIL could discriminate between uncomplicated and severe CAP. AECOPD patients showed significantly different levels of LTF and TRAIL compared to healthy subjects. Ensemble feature selection revealed that CAP and AECOPD can be discriminated by IL-6, resistin, together with IL-2R. These factors even allow the differentiation between COPD patients suffering from an exacerbation or pneumonia. DISCUSSION: Taken together, we identified immune mediators in patient plasma that provide information on differential diagnosis and disease severity and can therefore serve as biomarkers. Further studies are required for validation in bigger cohorts.
format Online
Article
Text
id pubmed-10277477
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102774772023-06-20 Novel protein biomarkers for pneumonia and acute exacerbations in COPD: a pilot study Jung, Anna Lena Han, Maria Griss, Kathrin Bertrams, Wilhelm Nell, Christoph Greulich, Timm Klemmer, Andreas Pott, Hendrik Heider, Dominik Vogelmeier, Claus F. Hippenstiel, Stefan Suttorp, Norbert Schmeck, Bernd Front Med (Lausanne) Medicine INTRODUCTION: Community-acquired pneumonia (CAP) and acute exacerbations of chronic obstructive pulmonary disease (AECOPD) result in high morbidity, mortality, and socio-economic burden. The usage of easily accessible biomarkers informing on disease entity, severity, prognosis, and pathophysiological endotypes is limited in clinical practice. Here, we have analyzed selected plasma markers for their value in differential diagnosis and severity grading in a clinical cohort. METHODS: A pilot cohort of hospitalized patients suffering from CAP (n = 27), AECOPD (n = 10), and healthy subjects (n = 22) were characterized clinically. Clinical scores (PSI, CURB, CRB65, GOLD I-IV, and GOLD ABCD) were obtained, and interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-2-receptor (IL-2R), lipopolysaccharide-binding protein (LBP), resistin, thrombospondin-1 (TSP-1), lactotransferrin (LTF), neutrophil gelatinase-associated lipocalin (NGAL), neutrophil-elastase-2 (ELA2), hepatocyte growth factor (HGF), soluble Fas (sFas), as well as TNF-related apoptosis-inducing ligand (TRAIL) were measured in plasma. RESULTS: In CAP patients and healthy volunteers, we found significantly different levels of ELA2, HGF, IL-2R, IL-6, IL-8, LBP, resistin, LTF, and TRAIL. The panel of LBP, sFas, and TRAIL could discriminate between uncomplicated and severe CAP. AECOPD patients showed significantly different levels of LTF and TRAIL compared to healthy subjects. Ensemble feature selection revealed that CAP and AECOPD can be discriminated by IL-6, resistin, together with IL-2R. These factors even allow the differentiation between COPD patients suffering from an exacerbation or pneumonia. DISCUSSION: Taken together, we identified immune mediators in patient plasma that provide information on differential diagnosis and disease severity and can therefore serve as biomarkers. Further studies are required for validation in bigger cohorts. Frontiers Media S.A. 2023-06-05 /pmc/articles/PMC10277477/ /pubmed/37342494 http://dx.doi.org/10.3389/fmed.2023.1180746 Text en Copyright © 2023 Jung, Han, Griss, Bertrams, Nell, Greulich, Klemmer, Pott, Heider, Vogelmeier, Hippenstiel, Suttorp and Schmeck. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Jung, Anna Lena
Han, Maria
Griss, Kathrin
Bertrams, Wilhelm
Nell, Christoph
Greulich, Timm
Klemmer, Andreas
Pott, Hendrik
Heider, Dominik
Vogelmeier, Claus F.
Hippenstiel, Stefan
Suttorp, Norbert
Schmeck, Bernd
Novel protein biomarkers for pneumonia and acute exacerbations in COPD: a pilot study
title Novel protein biomarkers for pneumonia and acute exacerbations in COPD: a pilot study
title_full Novel protein biomarkers for pneumonia and acute exacerbations in COPD: a pilot study
title_fullStr Novel protein biomarkers for pneumonia and acute exacerbations in COPD: a pilot study
title_full_unstemmed Novel protein biomarkers for pneumonia and acute exacerbations in COPD: a pilot study
title_short Novel protein biomarkers for pneumonia and acute exacerbations in COPD: a pilot study
title_sort novel protein biomarkers for pneumonia and acute exacerbations in copd: a pilot study
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277477/
https://www.ncbi.nlm.nih.gov/pubmed/37342494
http://dx.doi.org/10.3389/fmed.2023.1180746
work_keys_str_mv AT jungannalena novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy
AT hanmaria novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy
AT grisskathrin novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy
AT bertramswilhelm novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy
AT nellchristoph novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy
AT greulichtimm novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy
AT klemmerandreas novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy
AT potthendrik novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy
AT heiderdominik novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy
AT vogelmeierclausf novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy
AT hippenstielstefan novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy
AT suttorpnorbert novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy
AT schmeckbernd novelproteinbiomarkersforpneumoniaandacuteexacerbationsincopdapilotstudy